Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Research Data
Search by expertise, name or affiliation
BACE1 inhibitor drugs in clinical trials for Alzheimer's disease
Robert Vassar
*
*
Corresponding author for this work
Neurology
Research output
:
Contribution to journal
›
Review article
›
peer-review
301
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'BACE1 inhibitor drugs in clinical trials for Alzheimer's disease'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Alzheimer's Disease
100%
Alzheimer's Disease Brain
14%
Alzheimer's Disease Patient
14%
Amyloid Precursor Protein
14%
BACE1 Inhibitor
100%
BACE1 Substrates
14%
Blood-brain Barrier
14%
Chronic Administration
14%
Clinical Trials
100%
Drug Target
14%
Etiology
14%
Human Trials
14%
Inhibitor Drug
100%
Mechanism-based
14%
MET Inhibitor
14%
Pharmaceutical Industry
14%
Secretase
14%
Sporadic Alzheimer's Disease
14%
Therapeutic Agents
14%
Therapeutic Potential
14%
Therapeutic Window
14%
β-site APP-cleaving Enzyme 1 (BACE1)
42%
Pharmacology, Toxicology and Pharmaceutical Science
Alzheimer's Disease
100%
Amyloid Precursor Protein
14%
Amyloid Protein
14%
Blood-Brain Barrier
14%
Clinical Trial
100%
Secretase
14%
Side Effect
14%
Therapeutic Window
14%